Accelerate Diagnostics announces preliminary 2018 fourth quarter and full-year financial results
Jan 06, 2019
Added 117 commercially contracted U.S. instruments in Q4, doubling the regional installed base
TUCSON, Ariz., Jan. 6, 2019 /PRNewswire/ — Accelerate Diagnostics, Inc. (NASDAQ: AXDX), today announced preliminary financial results for the quarter ending December 31, 2018. The company reported a 127.2% increase in U.S. instruments placed under commercial contract during the fourth quarter, and full-year revenue of $5.7 million, an increase of 35.7% from the prior year.
- Antimicrobial Stewards from Tampa General Hospital see improvements after implementing Accelerate Pheno
Jun 09, 2020
- Clinicians at Moffitt Cancer Center make a difference for patients by optimizing antibiotic therapy earlier
Mar 06, 2020